Yes. You can inject testosterone subcutaneously instead of intramuscularly, and the research shows it works just as well.
A 2022 systematic review in the Journal of Clinical Endocrinology and Metabolism concluded that subcutaneous testosterone therapy “results in comparable pharmacokinetics and mean serum testosterone levels” to intramuscular injection. A 2023 prospective randomized controlled trial found that trough testosterone levels were comparable between SubQ and IM injection by the 6-month mark, with 92% of participants successfully self-injecting by 3 months.
If your doctor told you that testosterone “must” be injected intramuscularly, that guidance is outdated. The data now supports both routes as safe and effective. The choice comes down to practical considerations: needle comfort, injection volume, self-administration ease, and personal preference.
Why Doctors Still Push Intramuscular Injection
Intramuscular testosterone injection has been the standard for almost 80 years. The first testosterone esters were developed in the 1930s, and IM injection became the default delivery method. Most clinical guidelines still reference IM as the primary route, not because SubQ is inferior, but because the IM evidence base is simply larger.
The 2018 Endocrine Society clinical practice guideline mentions subcutaneous injection only briefly, noting that “subcutaneous injections of testosterone esters have been used” without making definitive recommendations. This is not a rejection of SubQ—it is an acknowledgment that direct comparison studies were limited at the time of publication.
Since then, new data has emerged. The 2022 Figueiredo review analyzed available clinical trials, case series, and case reports on SubQ testosterone administration and found that “available evidence, though limited, suggests that SC testosterone therapy in doses similar to those given via IM route results in comparable pharmacokinetics and mean serum testosterone levels.”
The lag between evidence and guideline updates creates confusion. Patients read newer research, bring it to their doctors, and encounter resistance based on older training. The reality is that both routes work. The question is which works better for your specific situation.
How Subcutaneous Absorption Actually Works
Testosterone esters are lipophilic compounds. When injected into subcutaneous fat or muscle, they do not immediately enter the bloodstream. Instead, they diffuse slowly from the injection depot into the interstitial fluid, then enter the lymphatic system before reaching systemic circulation.
Once in the blood, esterases hydrolyze the testosterone ester, releasing free testosterone. This slow-release mechanism is what creates stable testosterone levels over days to weeks, depending on the ester.
The absorption pathway is similar whether you inject into muscle or fat. The key difference is tissue density and blood flow. Muscle has higher blood flow, which can create slightly faster initial absorption. Subcutaneous tissue has lower blood flow but a larger surface area for diffusion, which can result in more gradual release.
The 2022 Figueiredo review includes a schematic comparing IM and SubQ absorption pathways (Figure 2B). Both routes show the ester exiting the depot via diffusion, entering the interstitium, moving through lymphatics, and reaching circulation where hydrolysis occurs. The pharmacokinetic profiles are not identical, but they are clinically equivalent when dosing is matched.
What the Research Shows: 2022-2023 Evidence
Figueiredo et al. 2022 (J Clin Endocrinol Metab)
This systematic review compiled data from multiple studies on SubQ testosterone therapy using both long-acting esters (enanthate, cypionate) and ultra-long-acting esters (undecanoate). Key findings:
- SubQ administration at doses similar to IM resulted in comparable mean serum testosterone levels
- Trough concentrations remained within normal physiological range
- No significant safety concerns specific to the SubQ route
- Patients could self-administer with appropriate training
- The authors concluded that SubQ is “easier to self-administer and has the potential to improve patient adherence”
The review noted that direct head-to-head safety comparisons are still desirable, but the available evidence supports SubQ as a viable clinical option.
Baines et al. 2023 (J Pediatr Endocrinol Metab)
This prospective randomized controlled trial compared SubQ vs IM testosterone injections in 26 transgender adolescents over 6 months. While the population differs from cisgender men on TRT, the pharmacokinetic data is directly relevant:
- Trough testosterone levels were comparable between SubQ and IM groups by 6 months
- Peak testosterone levels were higher in the IM group at the 3-month mark but equalized over time
- Adverse effects were mild and limited to skin reactions in 12% of SubQ subjects
- Self-reported masculinization effects and quality of life were not statistically different between groups
- 92% of participants were self-injecting by the 3-month follow-up
This study demonstrates that SubQ achieves equivalent clinical and biochemical outcomes with a high self-injection success rate.
Laurenzano et al. 2021 (Transgender Health)
An 8-year single-center experience with SubQ testosterone in 84 transmasculine adolescents and young adults found that SubQ therapy was “effective and safe” with “no serious adverse events.” Mean testosterone levels reached the male range by 3 months and remained stable throughout treatment.
Dosing Protocol: SubQ vs IM
The dosing for SubQ testosterone is the same as IM. If you are prescribed 100mg of testosterone cypionate weekly via IM injection, you would inject 100mg weekly via SubQ.
Injection Volume
- SubQ: typically 0.5 to 1.0 mL per injection site
- IM: typically 1.0 to 2.0 mL per injection site
Subcutaneous tissue has less capacity than muscle. If your dose requires more than 1 mL, you may need to split the injection into two sites or stick with IM.
Needle Gauge
- SubQ: 25 to 29 gauge, 1/2 to 5/8 inch length
- IM: 22 to 23 gauge, 1 to 1.5 inch length
The smaller needle gauge is one of the primary advantages of SubQ injection. Many patients find 29-gauge needles significantly less painful than 23-gauge IM needles.
Injection Sites
- SubQ: abdomen (2 inches from navel), anterior thigh, upper buttocks
- IM: ventrogluteal, dorsogluteal, vastus lateralis (thigh), deltoid
SubQ injection sites are generally easier to access for self-administration.
Frequency
The injection frequency is determined by the ester, not the route. Testosterone cypionate and enanthate are typically injected every 7 to 14 days. Testosterone undecanoate is injected every 10 to 14 weeks. This does not change between SubQ and IM.
The Practical Advantages of SubQ
Easier Self-Administration
The 2023 Baines study found that 92% of participants were self-injecting by 3 months. This high success rate reflects the practical reality that SubQ injection is easier to learn and perform than IM injection.
IM injection requires proper angle (90 degrees), depth control, and aspiration technique to avoid intravascular injection. SubQ injection uses a shorter needle, a 45-90 degree angle depending on tissue depth, and does not require aspiration. The margin for error is larger.
Less Discomfort
A 29-gauge needle is significantly smaller than a 23-gauge needle. For patients with needle anxiety or injection site pain, this difference is meaningful. The Figueiredo review explicitly notes that SubQ is associated with “less discomfort compared with the IM route.”
Better Adherence Potential
Adherence is the silent killer of TRT protocols. Missed injections, delayed refills, and clinic scheduling conflicts all erode treatment consistency. SubQ injection removes barriers by making self-administration easier. The Figueiredo review concludes that SubQ “has the potential to improve patient adherence” for this reason.
BMI Independence
The Figueiredo review includes data showing that optimal SubQ doses were not influenced by BMI (Figure 5B). This suggests that SubQ absorption is consistent across body compositions, addressing a common concern that higher body fat might impair subcutaneous delivery.
Who Should Consider SubQ Injection
- Patients with needle anxiety or injection site pain
- Patients who want to self-inject but struggle with IM technique
- Patients on lower-volume doses (0.5-1.0 mL or less)
- Patients who travel frequently and need a more portable protocol
- Patients whose doctors are open to evidence-based protocol adjustments
Who Should Stick with IM
- Patients already stable and satisfied on IM protocols
- Patients requiring high-volume doses (>1.0 mL per injection)
- Patients whose insurance or clinic protocols do not support SubQ
- Patients with specific medical conditions where IM is clinically indicated
- Patients whose doctors are not comfortable with SubQ monitoring
There is no universal right answer. The best protocol is the one you can execute consistently.
Potential Side Effects and Considerations
Skin Reactions
The 2023 Baines study reported a 12% skin reaction rate in the SubQ group, all classified as mild. These were limited to localized irritation at the injection site. No serious adverse events occurred.
Absorption Variability
SubQ absorption can be more variable than IM in the first few months as your body adapts to the new injection route. Peak levels may be lower initially, then normalize. This is why lab monitoring at 4-6 weeks after switching is critical.
Injection Technique Learning Curve
While SubQ is easier than IM, it still requires proper technique. Injecting too shallow can cause leakage. Injecting into scar tissue can impair absorption. Rotating injection sites prevents lipodystrophy.
Clinic and Insurance Barriers
Some clinics do not support SubQ injection because their protocols are built around IM. Some insurance plans may not cover the necessary supplies (smaller-gauge needles) if they are not explicitly prescribed. These are administrative barriers, not clinical ones, but they matter.
Implementation Protocol: Making the Switch
If you want to switch from IM to SubQ testosterone injection, follow this sequence:
Consult your prescribing physician. Bring the Figueiredo 2022 and Baines 2023 studies. Ask specifically about their experience with SubQ and their willingness to support a protocol change.
Start at the same dose. Do not reduce your dose when switching routes. The pharmacokinetic data supports equivalent dosing.
Use proper injection technique.
- Pinch a fold of skin at the injection site
- Insert needle at 45-90 degrees depending on tissue depth
- Inject slowly (10-15 seconds per 0.5 mL)
- Hold for 10 seconds before withdrawing
- Apply gentle pressure with alcohol pad
Monitor labs at 4-6 weeks. Check total testosterone, free testosterone, estradiol, and hematocrit. Compare trough levels to your previous IM baseline.
Track symptoms. Note energy, libido, mood, and injection site reactions. Subjective response matters as much as lab numbers.
Adjust if needed. If trough levels are lower than expected, your physician may increase dose or frequency. If skin reactions occur, rotate sites or consider a different needle gauge.
Medical Disclaimer
This article is for informational purposes only and does not constitute medical advice. Testosterone replacement therapy should only be initiated and monitored by a qualified healthcare provider. Injection route, dose, and frequency must be individualized based on your medical history, lab results, and treatment goals. Never modify your protocol without physician supervision.
Bottom Line
Subcutaneous testosterone injection is not experimental. It is a clinically validated delivery route with peer-reviewed evidence supporting its safety and efficacy. The 2022 Figueiredo systematic review and the 2023 Baines randomized controlled trial demonstrate that SubQ achieves comparable testosterone levels to IM with easier self-administration and less discomfort.
If you struggle with IM injection—whether due to needle anxiety, injection site pain, or logistical barriers—SubQ is worth discussing with your doctor. The data supports it. The practical advantages are real. The only barrier is outdated clinical inertia.
Track your labs. Track your symptoms. Make evidence-based decisions. That is how you optimize testosterone therapy for the long term.